GlassScriptPhysician profile
Mazhar Salim
NPI 1013075449
$993.36
in general payments reported to CMS, 2019-2025
13 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $49.08 · 2021: $120 · 2022: $53.09 · 2023: $148 · 2024: $248 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $236.86 | 2019-2025 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $124.74 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $119.68 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $97.94 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $95.27 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Biohaven Pharmaceuticals, INC. | $69.44 | 2021 | |
| Allergan, INC. | $64.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $56.61 | 2019 | |
| Lundbeck LLC | $38.38 | 2023-2024 | Abilify Maintena |
| Bioxcel Therapeutics, INC. | $36.54 | 2023 | Igalmi |
| Axsome Therapeutics, INC. | $21.88 | 2023 | Auvelity |
| Abbvie INC. | $18.47 | 2025 | |
| Vanda Pharmaceuticals INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazhar Salim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.